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The study shows constitutive activation of the Notch pathway in various types of malignancies. However, it remains unclear how the
Notch pathway is involved in the pathogenesis of osteosarcoma. We investigated the expression of the Notch pathway molecules in
osteosarcoma biopsy specimens and examined the effect of Notch pathway inhibition. Real-time PCR revealed overexpression of
Notch2, Jagged1, HEY1, and HEY2. On the other hand, Notch1 and DLL1 were downregulated in biopsy specimens. Notch pathway
inhibition using g-secretase inhibitor and CBF1 siRNA slowed the growth of osteosarcomas in vitro. In addition, g-secretase inhibitor-
treated xenograft models exhibited significantly slower osteosarcoma growth. Cell cycle analysis revealed that g-secretase inhibitor
promoted G1 arrest. Real-time PCR and western blot revealed that g-secretase inhibitor reduced the expression of accelerators of
the cell cycle, including cyclin D1, cyclin E1, E2, and SKP2. On the other hand, p21
cip1 protein, a cell cycle suppressor, was upregulated
by g-secretase inhibitor treatment. These findings suggest that inhibition of Notch pathway suppresses osteosarcoma growth by
regulation of cell cycle regulator expression and that the inactivation of the Notch pathway may be a useful approach to the
treatment of patients with osteosarcoma.
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Osteosarcoma is the most common primary bone cancer
occurring mainly in children (Gibbs et al, 2002). After initial
diagnosis is made by biopsy, treatment consists of preoperative
chemotherapy, followed by definitive surgery and postoperative
chemotherapy. Survival has improved over the past several
decades. Indeed, patients with non-metastatic disease have a 70%
chance of long-term survival. Unfortunately, patients with meta-
static disease at diagnosis or those who have recurrent disease have
a poor prognosis, with only 20% surviving at 5 years, indicating
that new therapeutic options for them need to be actively explored.
In cancer cells, dysregulation of cell division and apoptotic
processes contribute to drug resistance and to metastatic potential
(Igney and Krammer, 2002; Lafleur et al, 2004). It is reported that
the cell cycle regulatory pathway centred around pRb is frequently
somatically inactivated in osteosarcomas (Horowitz et al, 1990).
Although such dysregulation may represent a potent source of new
therapeutic targets, the molecular mechanisms that regulate
osteosarcoma cell proliferation are largely unknown.
Members of the Notch family are highly conserved trans-
membrane receptors that influence the proliferation and apoptosis
of diverse types of cells in a variety of organisms (Artavanis-
Tsakonas et al, 1999). Activation of Notch signalling requires
binding of its ligands (Jagged, DLL), followed by proteolytic
release of the Notch intracellular domain (NIC) and its trans-
location to the nucleus (De Strooper et al, 1999). Notch
intracellular domain interacts with CSL transcription factors
(CBF1/RBP-Jk, Su(H), Lag-1) and converts them from repressors
to activators, promoting transcription of downstream genes
involved in various differentiation programmes (Davis and Turner,
2001). Recent studies have also shown constitutive activation of the
Notch pathway in various types of malignancies. The oncogenic
potential of Notch has been reported in human T-cell acute
lymphoblastic leukaemia (Grabher et al, 2006), non-small cell lung
cancer (Dang et al, 2000), ovarian carcinomas (Park et al, 2006),
and pancreatic cancer (Miyamoto et al, 2003). Although, it was
recently reported that DLL1, Notch1, Notch2, and HES1 are
expressed in osteosarcoma cell lines, whether expression of Notch
signalling molecules in osteosarcoma patient specimens is aberrant
has not been clarified.
To explore the involvement of aberrant Notch signalling in the
pathogenesis of osteosarcoma, we investigated the expression of
the Notch pathway molecules in osteosarcoma patient specimens
and examined the effects of Notch pathway inhibition by
g-secretase inhibitor (GSI) and CBF1 siRNA. We found that
Notch2, Jagged1, HEY1, and HEY2 were upregulated in the
osteosarcoma biopsy specimens. On the other hand, Notch1 and
DLL1 were downregulated in biopsy specimens. In addition,
Notch pathway inhibition prevented the growth of osteosarcoma
in vitro and in vivo by cell cycle regulation.
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Cell culture
Human osteosarcoma cell lines, HOS, 143B, Saos-2, and U2OS cells
were purchased from the American Type Culture Collection
(ATCC). Cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS, penicillin (100Uml
 1), and
streptomycin (100mgml
 1). Human osteoblast cells (NHOst) were
purchased from Sanko Junyaku (Tokyo, Japan). Cells were
cultured with OBM (Cambrex, East Rutherford, NJ, USA) or
DMEM supplemented with 10% FBS. All cells were grown in a
humidified atmosphere containing 5% CO2 at 371C.
Patient specimens
All osteosarcoma biopsy specimens were obtained from primary
lesions. Biopsy was carried out before chemo- or radiotherapy to
make the diagnosis. Normal bone tissue was obtained from femur
during total hip arthroplasty.
Real-time PCR (RT–PCR)
For real-time PCR (RT-PCR), total RNA was DNase-treated and
reverse transcribed using oligo(dT) primers as described by the
manufacturer (Invitrogen, Carlsbad, CA, USA). Reactions were run
using SYBR Green (BIO-RAD, Hercules, CA, USA) on a MiniOpticon
machine (BIO-RAD). The comparative Ct (DDCt) method was used to
determine fold change in expression using bII-microglobulin.
Each sample was run minimally at three concentrations
in triplicate. All primer sets amplified 100 to 200bp fragments.
The primer sequences used were as follows: for Notch1:
5-GTGACTGCTCCCTCAACTTCAAT-3, 5-CTGTCACAGTGGCCG
TCACT-3; Notch2: 5-AAAAATGGGGCCAACCGAGAC-3, 5-TTCA
TCCAGAAGGCGCACAA-3; Jagged1: 5-CGGGATTTGGTTAATGG
TTATC-3, 5-ATAGTCACTGGCACGGTTGTAGCAC-3; DLL1: 5-C
CTACTGCACAGAGCCGATCT-3, 5-GCAGGTGGCTCCATTCTTG
C-3; HES1: 5-AGGCGGACATTCTGGAAATG-3, 5-CGGTACTTC
CCCAGCACACTT-3; HEY1: 5-CGAGGTGGAGAAGGAGAGTG-3,
5-CTGGGTACCAGCCTTCTCAG-3; HEY2: 5-GAACAATTACTCG
GGGCAAA-3, 5-TCAAAAGCAGTTGGCACAAG-3; CBF1: 5-CGCA
TTATTGGATGCAGATG-3, 5-CAGGAAGCGCCATCATTTAT-3;
cyclin D1: 5-ACAAACAGATCATCCGCAAACAC-3, 5-TGTTGGG
GCTCCTCAGGTTC-3; cyclin E1: 5-CCACACCTGACAAAGAAGA
TGATGAC-3, 5-GAGCCTCTGGATGGTGCAATAAT-3; cyclin E2:
5-TGTTGGCCACCTGTATTATCTGG-3; 5-ATCTGGAGAAATCAC
TTGTTCCTATTTC-3; SKP2: 5-TGGGAATCTTTTCCTGTCTG-3,
5-GAACACTGAGACAGTATGCC-3; c-Myc: 5-GCCACGTCTCCAC
ACATCAG-3, 5-TGGTGCATTTTCGGTTGTTG-3; bII-microglobu-
lin: 5-TCAATGTCGGATGGATGAAA-3, 5-GTGCTCGCGCTACT
CTCTCT-3.
MTT assay
Cells were incubated with substrate with MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 4h,
and washed with PBS and lysed to release formazan from cells.
Then cells were analysed in a Safire microplate reader (BIO-RAD)
at 562nm. g-Secretase inhibitor X was used for MTT assay.
CBF1 siRNA was purchased from Santa Cruz (Santa Cruz, CA,
USA). Lipofection of siRNA was carried out every other day as
recommended in the supplier’s protocol using FuGENE 6 (Roche,
Basel, Switzerland).
Cell death detection
Cell death detection ELISA
plus (Roche) was used to detect
cell death as per manufacturer’s protocol. Briefly, cells were
incubated with different concentrations of camptothecin (CAM)
for 4h at 371C. Before and after lysis, cells were centrifuged and the
supernatant was analysed.
Immunohistochemistry
The following primary antibodies were used: anti-HES1 (diluted
1:200; Chemicon, Temecula, CA, USA) and ki67 (Zymed
Laboratories, San Francisco, CA, USA). The following secondary
antibodies were used; fluorescein rhodamine-conjugated donkey
antirabbit IgG antibody (diluted 1:200; Chemicon). The cells were
counterstained with Hoechst 33258 (Molecular Probes, Carlsbad,
CA, USA) to identify nuclei. Immunohistochemistry with each
second antibody alone without primary antibody was carried out
as a control.
Western blot
Cells were lysed using NP40 lysis buffer (0.5% NP40, 10mM Tris-
HCl (pH 7.4), 150mM NaCl, 3mM pAPMSF (Wako Chemicals,
Kanagawa, Japan), 5mgml
 1 aprotinine (Sigma, St Louis, MO,
USA), 2mM sodium orthovanadate (Wako Chemicals), and 5mM
EDTA). Lysates were subjected to SDS–PAGE and subsequent
immunoblotting with antibodies to actin, cyclin D1, E1, E2, p21,
SKP2, pRb, c-Myc (Santa Cruz), and Notch2-inter cellular domain
(Abcam, Cambridge, UK). Detection was carried out using the ECL
detection system (Amersham, Chalfont St Giles, UK).
Animal experiments
In all, 143B cells (1 10
6) were mixed with collagen gel in a 1:1
volume, and inoculated subcutaneously in 5-week-old nude mice.
The mice were randomly assigned to receive either GSI XX
(10mgkg
 1; CALBIOCHEM, Basel, Switzerland) or an equal
volume of physiological saline solution (control). g-Secretase
inhibitor XX and saline solution were administered by intraperi-
toneal injection. The treatment with GSI XX was initiated 1 week
after tumour inoculation when the tumours had grown to visible
size. Tumour size was measured with calipers weekly, and tumour
volume was calculated using the formula LW
2/2 (with L and W
representing the length and width of tumours). All experimental
procedures were carried out in compliance with the guiding
principles for the Care and Use of Animals described in the
American Journal of Physiology and with the Guidelines estab-
lished by the Institute of Laboratory Animal Sciences, Faculty of
Medicine, Kagoshima University. All efforts were made to
minimise animal suffering, to reduce the number of animals used,
and to utilise possible alternatives to in vivo techniques.
Cell cycle analysis
Cell cycle analysis was committed and carried out by Reprocell
(Tokyo, Japan). At 48h after GSI X treatments, cells were collected
Figure 1 Notch pathway molecules are overexpressed in osteosarcoma patient specimens. Total RNA extracted from osteosarcoma biopsy specimens
was used for real-time PCR. Ten of ten human biopsy specimens of osteosarcoma increased Notch2 1.3–57.3-fold. Notch1 was decreased 0.03–0.86-fold
in 9 of 10 biopsy specimens. Jagged1 was upregulated 3.6–309-fold in 10 of 10 biopsy specimens. In 9 of 10 human biopsy specimens, DLL1 was decreased
0.02–0.35-fold. HES1 was upregulated in 6 of 10 and downregulated in 4 of 10 biopsy specimens. HEY1 was upregulated 1.6–12-fold in 8 of 10 biopsy
specimens. HEY2 was upregulated 2.9–106-fold in 9 of 10 biopsy specimens. The comparative Ct (DDCt) method was used to determine fold change in
expression using bII-microglobulin. Each sample was run minimally at three concentrations in triplicate.
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sby trypsinisation and washed with DPBS. Cells were fixed in 70%
(v/v) ethanol at 41C, washed with PBS, and resuspended with 500ml
of staining solution (PBS pH 7.4, 100mgml
 1 DNase-free RNase,
1mgml
 1 propidium iodide). Cells were then analysed by flow
cytometry using an FACS Vantage SE (Becton Dickinson, Franklin
Lakes, NJ, USA). Data were gated using pulse width and pulse
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sarea to exclude doublets, and the percent of cells present in
each phase of the cell cycle was calculated using FlowJo software
(Tree Star, Ashland, OR, USA).
Statistics
Each sample was analysed in triplicate, and experiments were
repeated three times. In all figures, error bars are s.d. All statistical
analyses were carried out using Microsoft Office Excel (Microsoft,
Albuquerque, New Mexico, USA) and STASTISCA (StatSoft, Tulsa,
OK, USA). Differences between mean values were evaluated by the
unpaired t-test, and differences in frequencies were evaluated by
Fisher’s exact test. Differences were considered significant at Po0.05.
RESULTS
Notch2, Jagged1, HEY1, and HEY2 are overexpressed in
osteosarcoma patient specimens
Real-time PCR was carried out to examine the gene expression of
Notch pathway molecules. Real-time PCR revealed that 10 of 10
human biopsy specimens of osteosarcoma increased Notch2 1.3–
57.3-fold (Figure 1). On the other hand, Notch1 was decreased
0.03–0.86-fold in 9 of 10 human biopsy specimens (Figure 1). To
further examine Notch pathway molecules expression, we carried
out RT-PCR for Notch ligands and Notch target genes. It was
reported that Jagged1 and DLL1 are Notch ligands (Bettenhausen
et al, 1995; Oda et al, 1997). Jagged1 was upregulated 3.6–309-fold
in 10 of 10 human biopsy specimens of osteosarcoma (Figure 1).
On the other hand, DLL1 was decreased 0.02–0.35-fold in 9 of
10 human biopsy specimens (Figure 1). It was reported that HES
and HEY are Notch target genes (Jarriault et al, 1995; Maier and
Gessler, 2000). HES1 was upregulated in 6 of 10 and downregulated
in 4 of 10 biopsy specimens (Figure 1). HEY1 was upregulated
1.6–12-fold in 8 of 10 human biopsy specimens (Figure 1). HEY2
was upregulated 2.9–106-fold in 9 of 10 human biopsy specimens
(Figure 1). Immunohistochemical examination revealed that HES1 was
accumulated in the nuclei of human osteosarcoma samples (Supple-
mentary data A). These findings suggest that the Notch signalling
pathway is activated in human osteosarcomas.
Inhibition of Notch pathway prevents osteosarcoma
growth in vitro and in vivo
To determine whether Notch pathway activation is required for
osteosarcoma cell growth and survival, we used GSI X, a
pharmacological agent known to effectively block Notch activation
by inhibiting the proteolysis and translocation of NIC to the
nucleus. We carried out RT-PCR to determine which
concentration of GSI X effectively inhibited Notch activity in
osteosarcoma cells, and then measured the expression of the
Notch pathway target HES1. In 143B cell, GSI X at 5mM reduced
mRNA levels of HES1 in 143B cells more than 60% (Figure 2A).
As GSI-18 was used to prevent glioma cell growth at 2–10mM
(Fan et al, 2006), we decided that 5mM was appropriate concen-
tration for osteosarcoma. In addition, western blot showed that
5mM GSI X decreased the Notch2-inter cellular domain (Figure 2B).
These data suggest that Notch signalling is blocked as expected
with GSI. We then assessed the tumour growth in vitro under
GSI treatment. MTT assay revealed that GSI treatment slowed the
growth of HOS and 143B in dose-dependent fashion, suggesting
that this concentration is sufficient to induce the antitumour
effect mediated by GSI (Figure 2C). On the other hand, cell death
detection assay revealed that GSI did not affect cell death
(Supplementary data B). To confirm the effects of Notch pathway
inhibition, we examined those of CBF1 siRNA. When NIC
translocates to the nucleus, it binds CBF1 and activates transcrip-
tion of target genes. Real-time PCR revealed that siRNA effectively
knocked down CBF1 mRNA (Figure 2D). MTT assay revealed that
viable cell mass was reduced by CBF1 siRNA in HOS and 143B
(Figure 2E). We next examined the effects of Notch pathway
blockade on tumour formation in vivo. Nude mice were inoculated
with 143B osteosarcoma cells intradermally, and palpable tumours
formed in 7 days. The mice were then injected intraperitoneally
in GSI or DMSO as a control as reported earlier (van Es et al,
2005). The injections were repeated every other day. Results
showed significant inhibition of tumour growth in the GSI-treated
vs DMSO-treated control group. All of the 6 GSI-treated tumours
exhibited significantly slower growth than DMSO-treated tumours
(Figure 3A and B). Kaplan–Meier analysis showed that GSI
administration conferred a significant survival benefit (Figure 3C).
Histological analysis indicated that GSI induced growth arrest. The
control tumours exhibited a number of cells positive for Ki67, a
marker of cell proliferation. In contrast, GSI-treated tumours
exhibited little evidence of proliferation, as evidenced by lack of
Ki67 positivity. The number of Ki67-positive cells was decreased to
36% of control level by GSI administration (Figure 3D).
Notch pathway regulates osteosarcoma cell cycle
We examined cell cycle characteristics by flow cytometry. When
HOS cells were cultured without GSI, 54.6% of cells were in G1
phase. On the other hand, when cultured with GSI, 64.8% of cells
were in G1 phase. In the case of 143B cells cultured without GSI,
39.8% of cells were in G1 phase, whereas 53.3% of cells were in G1
phase when treated with GSI (Figure 4A). These findings suggested
that GSI promoted G1 arrest. We then examined the transcription
of genes related to the cell cycle. Real-time PCR revealed that
GSI prevented the transcription of accelerators of the cell cycle,
including cyclin D, cyclin E1, cyclin E2, SKP2, and c-Myc
(Figure 4B). In mammalian cells, cyclin D, cyclin E, and p21
cip1
are short-lived proteins that are controlled by ubiquitin-dependent
proteolysis. Western blot examination showed that GSI reduced
the levels of expression of cyclin E1, cyclin E2, c-Myc, p-Rb, and
SKP2 proteins. We next examined the expression of p21
cip1, and
found that p21
cip1 protein was upregulated by GSI treatment
(Figure 4C). These findings suggested that GSI promoted G1 arrest
by inhibition of G1-S phase progression.
DISCUSSION
Deregulation of Notch signalling is implicated in the development
of various cancers, and Notch blockade appears to affect the
survival and proliferation of multiple types of cancer (Radtke and
Raj, 2003; Politi et al, 2004; Weng and Aster, 2004). For example,
Notch is activated by translocation or mutation in more than half
of T-cell acute lymphoblastic leukaemias, and anti-Notch treat-
ments have been shown to slow the growth of acute lymphoblastic
leukaemia growth in vitro (Weng et al, 2004). In addition,
combining GSIs and anticancer drugs improve anticancer effect
(Meng et al, 2009; Real et al, 2009). In this study, we found that
Notch2, Jagged1, HEY1, and HEY2 were overexpressed in human
osteosarcoma specimens. On the other hand, expression of Notch1
and DLL1 was downregulated in biopsy specimens. Recently,
Zhang et al (2008) reported that osteosarcoma cell lines, including
OS187, COL, SAOS2, and LM7, expressed Notch-related molecules.
Real-time PCR revealed that Notch1 expression was upregulated
in three of four cell lines. Notch2 expression was upregulated in
two of four cell lines, and HES1 expression was upregulated in
two of four cell lines. These results suggested that expression of
Notch-related genes differs markedly among cell lines and patient
specimens. Zhang et al (2008) carried out RT–PCR for two
osteosarcoma patient specimens and found that both expressed
Notch1, Notch2, Notch4, HES1, and HERP2 mRNA, although they
did not present RT–PCR data. We also carried out RT–PCR
using osteosarcoma biopsy specimens and detected the PCR
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Figure 2 Inhibition of Notch pathway prevents proliferation of osteosarcoma in vitro. Real-time PCR revealed four human osteosarcoma cell lines that
express Notch2 (B). We carried out RT–PCR to determine which concentration of g-Secretase inhibitor (GSI) X effectively inhibited Notch activity in
osteosarcoma cells, and then measured the expression of the Notch pathway target HES1. g-Secretase inhibitor X at 5mM reduced mRNA levels of HES1 in
143B cells more than 60% (error bar means s.d.) (A). Western blot analysis showed that 5mM GSI treatment reduced Notch2 intercellular domain (B).
Growth of viable HOS and 143B cells over 3 days was slowed in dose-dependent fashion by GSI X (C). Real-time PCR revealed that siRNA knocked down
CBF1 mRNA about 69% (D). Growth of HOS and 143B cells was slowed by CBF1 siRNA (E).
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samplicon of Notch1 in all specimens after 25-cycle reaction,
although RT–PCR revealed that expression of Notch1 was
decreased in osteosarcoma human specimens compared with
normal bone.
To explore how Notch pathway activation contributes to
osteosarcoma growth, we attempted to block the Notch pathway.
Treatment of osteosarcoma cells with GSI to block Notch acti-
vation prevented osteosarcoma growth in vitro and in vivo.
Our findings suggested an association between activation of Notch
signalling and pro-oncogenic effects in the progression of human
osteosarcoma. Although GSIs inhibit the cleavage and activation of
Notch receptors (Deftos et al, 2000), they neither specifically
inhibit Notch receptors nor inhibit cleavage of a number of other
transmembrane proteins (Esler et al, 2000; Zhang et al, 2000; Ni
et al, 2001; Marambaud et al, 2002). When we used CBF1 siRNA,
a Notch cooperative transcriptional factor, siRNA also inhibited
osteosarcoma growth effectively. These findings suggest that
inhibition of Notch signalling prevents osteosarcoma growth.
The role of GSIs in inhibiting the growth of osteosarcomas showed
in this study is consistent with the findings of earlier studies of
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Figure 3 Notch pathway inhibition blocks osteosarcoma xenograft growth in vivo and prolongs survival. In all, 143B cells (1 10
6) were inoculated
subcutaneously. Established 143B tumours were measured and then injected with g-secretase inhibitor (GSI) or DMSO intraperitoneally. The tumour
volume at day 7 was set at 1, and tumour volumes at subsequent time points were calculated. g-Secretase inhibitor significantly inhibited tumour growth at
day 31 compared with DMSO. The following decreases in tumour volume were observed in GSI compared with DMSO treatment: day 25: 37.9%; day 31:
26.3%; day 37: 19.7%; and day 43: 18.6% (A and B). Kaplan–Meier survival curves from GSI treatment groups (black) and DMSO control (red). Kaplan–
Meier analysis showed that GSI administration conferred a significant survival benefit (C; n¼6, Po0.05). Immunohistochemical examination of ki67 was
carried out in xenograft tumours. Ki67 staining revealed that proliferation of osteosarcoma cells was decreased by GSI treatment. The number of Ki67-
positive cells was decreased to 36% of control revel by GSI administration at day 35 (D; error bar means s.d.).
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sother malignancies (Pece et al, 2004; Curry et al, 2005; Park et al,
2008; Bin Hafeez et al, 2009; Meng et al, 2009; Real et al, 2009).
Although oncoproteins are not usually tumorigenic when ex-
pressed alone, constitutively active NIC expression promotes
papillary tumorigenesis (Klinakis et al, 2006). These findings
showed that the Notch pathway is a strong activator of cell
proliferation. Flow cytometry and ki67 staining showed that GSI
promoted G1 arrest in osteosarcoma in vitro and inhibited tumour
growth in vivo. We also found that GSI treatment regulated the
expression of cell cycle regulators by Notch inhibition. Real-time
PCR and western blot analysis revealed that cyclin D, E, SKP2,
c-Myc, and pRB were downregulated, and p21
Cip1 was upregulated
upon Notch inhibition with GSI. Cyclins D, E, pRb, c-Myc, and
SKP2 have been reported to promote G1-S phase progression
(Swanton, 2004; Hwang and Clurman, 2005). It has been reported
that cyclins D, E, and SKP2 are direct targets of Notch (Leong
and Karsan, 2006). In addition, SKP2 has been reported to be a
component of ubiquitin E3 ligase regulating G1/S transition by
degradation of p21
cip1 (Yu et al, 1998). p21
cip1 can bind to various
CDKs, including cyclin D/CDK4, cyclin E, and cyclin A/CDK2, and
inhibits their kinase activity. Suppression of the c-Myc oncogene
induces cellular senescence and tumour regression in osteo-
sarcoma (Wu et al, 2007). Our findings suggest that Notch signal-
ling has the same effect against osteosarcoma as in other
previously studied cancers. Recently, Zhang et al (2008) found,
using soft agar assay and xenografts, that downregulation of Notch
signalling by compound E suppressed osteosarcoma cell invasion.
On the other hand, downregulation of Notch signalling by GSI
(compound E) had no effect on cell proliferation or tumorigenesis.
One possible explanation for this discrepancy in findings may be
differences in cell lines used or GSI. We also carried out soft agar
assay, and found that GSI effectively inhibited colony formation in
soft agar assay (data not shown). Unfortunately, we have not yet
prepared metastatic tumour models using human osteosarcoma
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Figure 4 Notch pathway inhibition promotes G1 arrest. HOS and143B cells were treated with 5mM GSI. After 48-h treatment, cells were collected and
subjected to cell cycle analysis. When HOS cells were cultured without GSI, 54.6% of cells were in G1 phase. On the other hand, when cultured with GSI,
64.8% of cells were in G1 phase. In the case of 143B cells cultured without GSI, 39.8% of cells were in G1 phase, whereas 53.3% of cells were in G1 phase
when treated with GSI (A). Real-time PCR was carried out to quantify mRNAs of cell cycle-related genes. A 24-h treatment with GSI reduced the levels of
cyclin D, cyclin E1, E2, SKP2, and c-Myc transcription (error bar means s.d.; B). Western blot analysis of the levels of cell cycle-related genes. 48h treatment
with GSI reduced the levels of expression of cyclin E1, cyclin E2, c-Myc, pRb, and SKP2 proteins. Expression of P21
cip1 protein was upregulated by GSI
treatment. The experiment was triplicate with similar results (C; GSI: 5mM).
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scell lines, and have not yet examined the inhibitory effects on
metastasis of GSI and CBF1 siRNA in vivo. Nonetheless, both of
these studies provide independent support for the possibility that
Notch pathway inhibition may be useful in treating osteosarcoma.
It has been reported that GSI treatment induced apoptosis in
Kaposi’s sarcoma tumour cells (Curry et al, 2005). We carried out
cell death detection assay, but could not detect the differences after
GSI treatment in HOS and 143B HOS cell lines. These findings may
have been due to differences in cell viability between osteosarcoma
and Kaposi’s sarcoma cell lines.
In conclusion, our findings show that the Notch signalling
system is functionally activated in human osteosarcoma. This
novel finding adds to the understanding of osteosarcoma and may
be important in understanding the proliferation of osteosarcoma
cells. Furthermore, the finding of growth inhibition by GSI, a
Notch inhibitor, suggests that inactivation of Notch may be a
useful approach to the treatment of patients with osteosarcoma.
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